IPF Partners

IPF Partners is a private equity investment firm established in 2011 and based in Geneva, Switzerland. The company specializes in alternative financing within the European healthcare sector, focusing on emerging, commercial-stage companies in pharmaceuticals, biotechnology, medical technology, diagnostics, and healthcare IT. By directly investing in these areas, IPF Partners aims to support the growth and development of innovative healthcare solutions across Europe.

Edouard Guillet

Partner

Claire Lorenzi

CFO

Eleonore Martinez

Investment Principal

Jan Neu

Associate

23 past transactions

Faron Pharmaceuticals

Post in 2024
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Patient 21

Debt Financing in 2023
Patient21 operates a health platform focused on improving the doctor-patient connection, which they view as essential for effective healthcare. The company aims to modernize the healthcare experience by addressing the fragmented and outdated processes currently prevalent in the industry. By leveraging technology, Patient21 enhances dental clinics with management software that streamlines administrative tasks such as appointment scheduling and patient data management. They also provide electronic health records (EHR) to healthcare professionals, which helps improve diagnostic quality and reduce costs. Through these innovations, Patient21 seeks to facilitate better decision-making for both patients and physicians, ultimately promoting a more personalized and collaborative approach to healthcare.

Poxel

Post in 2022
Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. They believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC).

Faron Pharmaceuticals

Post in 2022
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Caresyntax

Series C in 2021
Caresyntax Inc. is a Boston-based company that provides a digital surgery platform designed to enhance surgical performance and improve patient outcomes. The platform integrates various data sources, including video, audio, and clinical information, to deliver actionable insights for operating room (OR) teams. By leveraging advanced analytics and IoT technology, Caresyntax enables healthcare organizations to benchmark surgical outcomes, optimize resource utilization, and reduce variability in clinical performance. The software is utilized in over 4,000 operating rooms globally, supporting more than 30,000 surgeons and impacting the care of over 2 million patients each year. The company offers solutions that facilitate real-time reporting and workflow automation, allowing hospitals to mitigate risks and improve surgical training without the extensive investment typical of traditional big data analytics. Founded in 1991, Caresyntax continues to advance the use of technology in healthcare to drive better surgical practices and outcomes.

Lumeon

Series D in 2020
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Caresyntax

Venture Round in 2019
Caresyntax Inc. is a Boston-based company that provides a digital surgery platform designed to enhance surgical performance and improve patient outcomes. The platform integrates various data sources, including video, audio, and clinical information, to deliver actionable insights for operating room (OR) teams. By leveraging advanced analytics and IoT technology, Caresyntax enables healthcare organizations to benchmark surgical outcomes, optimize resource utilization, and reduce variability in clinical performance. The software is utilized in over 4,000 operating rooms globally, supporting more than 30,000 surgeons and impacting the care of over 2 million patients each year. The company offers solutions that facilitate real-time reporting and workflow automation, allowing hospitals to mitigate risks and improve surgical training without the extensive investment typical of traditional big data analytics. Founded in 1991, Caresyntax continues to advance the use of technology in healthcare to drive better surgical practices and outcomes.

Lumeon

Series C in 2018
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

SpineGuard

Post in 2018
SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries, utilizing its proprietary Dynamic Surgical Guidance (DSG®) technology. This powerful, radiation-free sensing platform enhances the accuracy and safety of skeletal implant placement through real-time audio and visual feedback for surgeons. The company's flagship product, the PediGuard probe, is specifically designed for spine surgery, allowing surgeons to create pilot holes in vertebrae with precision. Equipped with a sensor that measures electrical conductivity, the PediGuard alerts surgeons to changes in bone and tissue types without the need for X-ray imaging. Available in various shapes and sizes, these devices cater to a wide range of surgical needs, from pediatric deformity corrections to adult degenerative conditions. With over 80,000 successful spinal procedures supported by PediGuard and substantial clinical evidence backing its efficacy, SpineGuard aims to address critical challenges in pedicle screw placement while improving patient outcomes and operational efficiency in the surgical environment.

Genesis Automation

Venture Round in 2018
Genesis Automation specializes in healthcare value-chain solutions aimed at enhancing patient safety and operational efficiency within healthcare organizations. The company has developed a clinical traceability platform that tracks the movement of essential supplies and equipment throughout the healthcare supply chain, from manufacturers to the point of care. By providing a suite of tools designed to ensure the accurate delivery of medication and devices, Genesis Automation helps hospitals and suppliers reduce costs and eliminate waste, ultimately improving the overall quality of patient care.

Genesis Automation

Venture Round in 2018
Genesis Automation is a single source, full-service automated system solutions provider. It designs and builds high-precision assembly, test, and special process equipment for a wide range of industries. Genesis Automation was founded in 1999 and is based in Cork, Ireland.

Lumeon

Debt Financing in 2017
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Mauna Kea Technologies

Post in 2017
Mauna Kea Technologies is a global medical device company dedicated to enhancing the diagnosis and treatment of cancer and other diseases through real-time in vivo microscopic visualization. Its primary product, Cellvizio®, is an advanced imaging platform that enables optical biopsies, allowing physicians to examine tissues at a cellular level during standard medical procedures. This technology aids in the early detection of pathologies and informs therapeutic decisions. The company markets Cellvizio products and accessories for medical diagnostics and research in France and over 40 countries worldwide, generating revenue primarily from these sales.

Impeto Medical

Debt Financing in 2016
Impeto Medical SAS is a privately owned medical device company based in Paris, France, established in 2005. The company specializes in manufacturing and marketing non-invasive devices that assess eccrine sweat gland activity. Its key products include SUDOSCAN+, which detects and monitors peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardiometabolic risks; and SUDOSCAN, which evaluates galvanic skin response to assess the sympathetic nervous system's behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical utilizes patented technology to analyze sudomotor function, enabling healthcare providers to screen large patient populations for early detection of diseases and complications. The company distributes its products through a network of distributors and has subsidiary locations in China and San Diego, California.

Neuravi

Debt Financing in 2016
Neuravi Limited, founded in 2009 and headquartered in Galway, Ireland, specializes in the design and development of innovative clot retrieval devices aimed at restoring blood flow in patients experiencing ischemic strokes caused by arterial blockages in the brain. The company's primary product, the EmboTrap revascularization device, is utilized in the treatment of acute ischemic strokes and is available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Neuravi's focus on neuro-interventional therapies is backed by extensive research into the mechanisms of stroke, particularly regarding the capture and removal of clots, which enhances treatment efficacy and improves patient outcomes. The company collaborates with international researchers and clinicians to foster the development of new solutions for this critical medical challenge. As of April 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

i-Optics

Debt Financing in 2016
i-Optics is a medical device company based in 's-Gravenhage, the Netherlands, that specializes in developing innovative corneal diagnostic solutions for eye care professionals. Founded in 2013, the company offers advanced technologies such as the Cassini Corneal Shape Analyzer, which utilizes color LED technology to accurately measure corneal astigmatism, aiding in premium intraocular lens (IOL) planning. This system helps cataract surgeons enhance patient outcomes and reduce unexpected refractive results. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system that employs scanning laser ophthalmoscopy (SLO) to diagnose various retinal diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma. Through its user-friendly and cost-effective solutions, i-Optics aims to support eye care providers in delivering high-quality care to their patients.

Genesis Automation

Debt Financing in 2016
Genesis Automation specializes in healthcare value-chain solutions aimed at enhancing patient safety and operational efficiency within healthcare organizations. The company has developed a clinical traceability platform that tracks the movement of essential supplies and equipment throughout the healthcare supply chain, from manufacturers to the point of care. By providing a suite of tools designed to ensure the accurate delivery of medication and devices, Genesis Automation helps hospitals and suppliers reduce costs and eliminate waste, ultimately improving the overall quality of patient care.

SpineGuard

Debt Financing in 2016
SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries, utilizing its proprietary Dynamic Surgical Guidance (DSG®) technology. This powerful, radiation-free sensing platform enhances the accuracy and safety of skeletal implant placement through real-time audio and visual feedback for surgeons. The company's flagship product, the PediGuard probe, is specifically designed for spine surgery, allowing surgeons to create pilot holes in vertebrae with precision. Equipped with a sensor that measures electrical conductivity, the PediGuard alerts surgeons to changes in bone and tissue types without the need for X-ray imaging. Available in various shapes and sizes, these devices cater to a wide range of surgical needs, from pediatric deformity corrections to adult degenerative conditions. With over 80,000 successful spinal procedures supported by PediGuard and substantial clinical evidence backing its efficacy, SpineGuard aims to address critical challenges in pedicle screw placement while improving patient outcomes and operational efficiency in the surgical environment.

Mainstay Medical

Post in 2015
Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

i-Optics

Venture Round in 2015
i-Optics is a medical device company based in 's-Gravenhage, the Netherlands, that specializes in developing innovative corneal diagnostic solutions for eye care professionals. Founded in 2013, the company offers advanced technologies such as the Cassini Corneal Shape Analyzer, which utilizes color LED technology to accurately measure corneal astigmatism, aiding in premium intraocular lens (IOL) planning. This system helps cataract surgeons enhance patient outcomes and reduce unexpected refractive results. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system that employs scanning laser ophthalmoscopy (SLO) to diagnose various retinal diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma. Through its user-friendly and cost-effective solutions, i-Optics aims to support eye care providers in delivering high-quality care to their patients.

EOS Imaging

Post in 2015
EOS imaging is a medical company revolutionizing the treatment continuum for the most common osteoarticular conditions (hip, knee and spine) and associated orthopedic surgeries. Its EOS® 2D/3D imaging system is specifically adapted to the needs of orthopedic surgeons and radiologists. This personalized imaging tool gives a precise 3D image of the patient's skeleton in the upright position that can be used to inform all aspects of care. The Company has obtained authorization to market the system in 48 countries. The Company is based in Paris, with a subsidiary in the United States in Cambridge, Massachusetts, as well as offices in Montreal (Canada) and Germany.

Mendor

Venture Round in 2014
Mendor is a Finnish company, committed to the design, development and marketing of advanced diabetes management products. Mendor has launched a revolutionary, discreet, easy to use, portable all-in-one blood glucose meter and web-based software application for the daily management of diabetes. Mendor has designed its products together with users and diabetes experts to address the needs of people with diabetes requiring regular blood glucose monitoring.

BONESUPPORT

Debt Financing in 2013
BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes designed to address fractures and bone voids resulting from trauma, infection, disease, or surgical interventions. The company's product portfolio includes CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, which are tailored for various orthopedic applications. CERAMENT V is an antibiotic eluting bone graft substitute that utilizes vancomycin to promote bone healing, while CERAMENT G employs gentamicin for similar purposes. The CERAMENT BONE VOID FILLER serves as a ceramic filler for gaps and voids in orthopedic settings. BONESUPPORT's mission is to improve the quality of life for patients with bone disorders, and the company operates additional locations in Germany, Switzerland, the United Kingdom, the United States, and India. Founded in 1999, BONESUPPORT AB is a subsidiary of Bonesupport Holding AB.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.